updates

### FULL PAPER

## MWCNTs-ZrO<sub>2</sub> as a reusable heterogeneous catalyst for the synthesis of *N*-heterocyclic scaffolds under green reaction medium

Bipasa Halder 🖻 | Flora Banerjee 🖻 | Ahindra Nag 🖻

Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur, 721302, India

#### Correspondence

Ahindra Nag, Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India. Email: ahinnag@chem.iitkgp.ernet.in

Funding information UGC, NEW DELHI, INDIA, Grant/Award Number: Ref No.- 21/06/2015(i)EU-V A simple, efficient, and facile heterogeneous multi-walled carbon nanotubeszirconia nanocomposite (MWCNTs-ZrO<sub>2</sub>) has been synthesized using natural feedstock coconut juice (água-de-coco do Ceará). The synthesized catalyst was characterized by Fourier transform infrared spectroscopy, X-ray diffraction, field emission scanning electron microscopy, and X-ray photoelectron spectroscopy analysis. The heterogeneous nanocomposite has been used for one-pot synthesis of various *N*-heterocyclic compounds like pyrazoles, 1,2-disubstituted benzimidazoles, 2-arylbenzazoles, and 2,3-dihydroquinazolin-4(1*H*)-ones under green reaction medium at room temperature. This novel method has several advantages, such as short reaction time, simple work-up, excellent yield, and green reaction conditions. The catalyst was recycled up to four times without significant loss in catalytic activity.

#### K E Y W O R D S

coconut juice, heterogeneous catalyst, MWCNTs-ZrO2, N-heterocyclic compounds, one-pot synthesis

## **1** | INTRODUCTION

Nitrogen-containing heterocyclic (azaheterocyclic) privileged scaffolds are widely dispersed in diverse fields such as synthetic organic chemistry, pivotal intermediates in drug industry, and biological and pharmaceutical areas.<sup>[1]</sup> Many pyrazole derivatives in synthetic chemistry, and amino pyrazoles are fascinating due their numerous properties, for example antifungal,<sup>[2]</sup> antimicrobial,<sup>[3]</sup> antiviral,<sup>[4]</sup> antihyperglycemic,<sup>[5]</sup> antitumor,<sup>[6]</sup> antiinflammatory,<sup>[7]</sup> analgesic,<sup>[8]</sup> antidepressant,<sup>[9]</sup> and anticonvulsant.<sup>[10]</sup> Of the many reported methods, most of the conventional approaches for the synthesis of pyrazoles are multicomponent reactions (MCRs) between a variety of aldehydes, malononitrile, and phenylhydrazine, which are synthesized using different types of catalyst, such as  $I_2$ ,<sup>[11]</sup> GO-TiO<sub>2</sub>,<sup>[12]</sup> polyethylene glycol:H<sub>2</sub>O,<sup>[13]</sup>

 $\label{eq:cuO/ZrO2} CuO/ZrO22, \end{tabular}^{[14]} \{ [HMIM]C(NO2)_3 \}, \end{tabular}^{[15]} Fe_3O_4 @Si@MoO22, \end{tabular}^{[16]} and CPS-CDMNPs. \end{tabular}^{[17]}$ 

Benzimidazole derivatives are fused *N*-heterocyclic skeletons that possess different biological properties such as anti-inflammatory,<sup>[18]</sup> antiprotozoal,<sup>[19]</sup> antihelminthic,<sup>[20]</sup> antimicrobial,<sup>[21]</sup> and anticancer activities,<sup>[22]</sup> 5-lipoxy genase inhibitory activities,<sup>[23]</sup> and antihypertensive activities.<sup>[24]</sup> Recently, several methods have emerged for the synthesis of 1,2-disubstituted benzimidazole derivatives in the presence of various catalysts such as ionic liquid-coated ZnO nanoparticles,<sup>[25]</sup> chitosan-supported Fe<sub>3</sub>O<sub>4</sub>,<sup>[26]</sup> Zn-proline,<sup>[27]</sup> and trifluoroethanol,<sup>[28]</sup> as well as benzimidazole derivatives synthesized from sodium dodecyl sulfate micelles,<sup>[29]</sup> Er(OTf)<sub>3</sub>,<sup>[30]</sup> and graphene sulfonic acid<sup>[31]</sup> catalysts. In addition, benzothiazole motifs are of outstanding significance due to their anticancer, antitumor, and antibacterial activities.<sup>[29]</sup> Several methodologies have

been disclosed for the synthesis of benzothiazoles, such as SDS micelles,  $^{[29]}$  nano-Fe $_2O_3,^{[32]}$  Bu<sup>t</sup>ONa,  $^{[33]}$  and oxalic/malonic acid.  $^{[34]}$ 

2,3-dihydroquinazolin-4(1*H*)-ones (DHQs) are *N*-hetero bicyclic compounds that have wide-ranging application as drug intermediates in the pharmaceutical and biological fields.<sup>[35]</sup> A number of methods have been established for the synthesis of DHQs over silica sulfuric acid,<sup>[36]</sup> beta cyclodextrin,<sup>[37]</sup> PEG-400,<sup>[35]</sup> Co-CNTs,<sup>[38]</sup> montmorillonite K-10,<sup>[39]</sup> and [Ce(L-Pro)<sub>2</sub>]<sub>2</sub>(Oxa).<sup>[40]</sup>

Heterogeneous catalysis is widely used and has become important for organic transformations in recent years.<sup>[41]</sup> Heterogeneous catalysts have many advantages over homogeneous catalysts, such as simple work-up, easy handling, reusability, and recoverability.<sup>[42]</sup> Notably, carbon nanotubes (CNTs) have attracted much attention in the field of heterogeneous catalysis<sup>[43]</sup> due to their high surface area, unique morphology, network, physical properties, and high electrical conductivity.<sup>[44]</sup> Recently, carbon nanotubes and their composites have been used as catalysts in many organic reactions as well as in the pharmaceutical industry.<sup>[38,45]</sup>

Among the various ceramic oxide nanoparticles, ZrO<sub>2</sub> has been used as a heterogeneous catalyst because of its high dielectric properties and thermal stability, acid–base properties and good mechanical strength.<sup>[46]</sup> Likewise, it has many applications in the field of science and technology.<sup>[47]</sup> Therefore multi-walled CNTs-ZrO<sub>2</sub> (MWCNTs-ZrO<sub>2</sub>) composites have been used in the field of Electromagnetic interference shielding.<sup>[48]</sup> Hybridization of MWCNTs-ZrO<sub>2</sub> composites has not been used in organic synthesis as a heterogeneous catalyst till now.

From the perspective of green chemistry, water has attracted attention as a reaction medium due to its cheap, environmentally friendly, nontoxic, and nonflammable properties.<sup>[49]</sup> Recently, plant parts have been used as a biocatalyst for organic transformations and generating nanoparticles also due to its mild reaction condition and eco-friendly aqueous medium.<sup>[50]</sup> In this context, coconut juice was introduced to the field of green nanotechnology. Coconut juice, known as água-de-coco do Ceará (ACC), is a sweet refreshing juice. Each 100 g of coconut juice contains water (94.99 g), proteins (0.72 g), fat (0.2 g), carbohydrates (3.71 g), fiber (1.1 g), sugar (2.61 g), electrolytes such as sodium (105 mg) and potassium (250 mg), minerals such as calcium (24 mg), magnesium (25 mg), and phosphorous (20 mg), ascorbic acid (2.4 mg), and pantothenic acid (0.043 mg).<sup>[51]</sup> It is already known that many fruit extracts, which are acidic in nature, have been used to synthesize ZrO<sub>2</sub> nanoparticles.<sup>[52]</sup> We report here the first synthesis of ZrO<sub>2</sub> and MWCNTs-ZrO<sub>2</sub> nanoparticles using ACC. Due to the acidic nature of ACC (pH = 5.06), it accelerates the formation of MWCNTs-ZrO<sub>2</sub> nanocomposite.

We describe the synthesis of MWCNTs- $ZrO_2$  nanocomposite from ACC and demonstrate its application as an efficient heterogeneous catalyst for the synthesis of pyrazoles by a multicomponent reaction of phenylhydrazine, malononitrile, aldehydes, synthesis of 1,2-disubstituted benzimidazoles and benzimidazoles from *o*-phenylenediamine and benzaldehydes, synthesis of benzothiazoles from *o*-aminothiophenol and benzaldehydes, and synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones from 2-aminobenzamide and benzaldehydes at room temperature (Scheme 1).

### 2 | RESULTS AND DISCUSSION

## 2.1 | Characterizations of the synthesized nanocomposite

ZrO<sub>2</sub> and MWCNTs-ZrO<sub>2</sub> were synthesized using a simple refluxing method from the natural feedstock ACC. The bonding, crystallinity, morphology, and atomic composition of the product were examined by Fourier transform infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), field emission scanning electron microscopy (FE-SEM), and X-ray photoelectron spectroscopy (XPS), respectively.

The FT-IR spectra of oxidized MWCNT, ZrO<sub>2</sub>, and MWCNTs-ZrO<sub>2</sub> composite were recorded in the range of 4,000-400 cm<sup>-1</sup> and the findings are displayed in Figure 1. The prominent peaks in spectra of oxidized MWCNT and  $ZrO_2$  at ~1,222 and 769 cm<sup>-1</sup> correspond to C-O bond stretching in different chemical environments and C-H bending vibration, respectively.<sup>[53]</sup> The two peaks in the spectra of ZrO<sub>2</sub> can be attributed to some metabolite and protein, such as the flavonoids and terpernoids present in coconut juice.<sup>[50f]</sup> Broad peaks centered at  $\sim$ 3,360, 1,611, and 1,349 cm<sup>-1</sup> appeared in the ZrO<sub>2</sub> spectrum due to the stretching and bending modes of the -OH group originating from adsorbed moisture.<sup>[53c,54]</sup> Notably, the weak and broad peak centered at  $\sim$ 968 cm<sup>-1</sup> is related to the Zr–O stretching mode. The FT-IR spectrum of the MWCNTs-ZrO<sub>2</sub> composite exhibited superimposition of the spectral features of both oxidized MWCNTs and ZrO<sub>2</sub>, accompanied by a change in peak intensity. Weak peaks centered at  $\sim$ 1,120 and 1,017 cm<sup>-1</sup> appeared in the spectrum for the MWCNTs-ZrO<sub>2</sub> composite due to the stretching mode of the aromatic C=C and C-O groups, respectively, presenting different chemical environment.<sup>[48]</sup> These findings clearly signify successful incorporation of ZrO<sub>2</sub> into MWCNTs.

110

100

90 100

90

80 100

90

O-H

%Transmittance

**SCHEME1** Synthesis of *N*-heterocyclic scaffolds in the presence of MWCNTs-ZrO<sub>2</sub>



FIGURE 1 FT-IR spectra of oxidized MWCNTs, ZrO<sub>2</sub>, and MWCNTs-ZrO<sub>2</sub> composite

ZrO,

XRD patterns of oxidized MWCNTs, ZrO<sub>2</sub>, and MWCNTs-ZrO<sub>2</sub> composites are shown in Figure 2. It can be seen that diffraction peaks for oxidized MWCNTs occur at  $2\theta = \sim 26^{\circ}$  and  $\sim 43^{\circ}$ , corresponding to the (002) and (100) planes, respectively, of MWCNTs.<sup>[55]</sup> Furthermore, the appearance of two broad peaks centered at around  $\sim 30^\circ$  (002) and 55° (100) confirmed the formation of amorphous from ZrO<sub>2</sub> (JCPDS no. 37–1,484).<sup>[56]</sup> XRD patterns for the MWCNTs-ZrO<sub>2</sub> composite had

FIGURE 2 XRD pattern of oxidized MWCNTs, ZrO<sub>2</sub>, and MWCNTs-ZrO<sub>2</sub> composite

diffraction peaks for both ZrO<sub>2</sub> and oxidized MWCNTs. Notably, the breadth of the oxidized MWCNT peak centered at  $\sim 26^{\circ}$  increased and the peak intensity of the same peak decreased with incorporation of amorphous ZrO<sub>2</sub> in MWCNTs. These findings clearly indicate incorporation of ZrO<sub>2</sub> into the MWCNT matrix.

FE-SEM images of ZrO<sub>2</sub>, oxidized MWCNTs, and MWCNTs-ZrO<sub>2</sub> composite are shown in Figure 3. ZrO<sub>2</sub> appears to exist as agglomerated spherical nanoparticles.<sup>[48]</sup>



**FIGURE 3** FE-SEM images of (a) ZrO<sub>2</sub>, (b) oxidized MWCNT, and (c) low-magnification and (d) highmagnification images of MWCNTs-ZrO<sub>2</sub> composite

Oxidized MWCNTs exhibit nanotube-like morphology stacked together. FE-SEM images of MWCNTs-ZrO<sub>2</sub> composite show that ZrO<sub>2</sub> nanoparticles are clearly incorporated in the MWCNT matrix. Notably, the regular shape of the MWCNTs remains intact even after synthesis with ZrO<sub>2</sub>.<sup>[48]</sup>

The valence state and elemental analysis of MWCNTs-ZrO<sub>2</sub> composite were analyzed by XPS (Figure 4). Figure 4a shows the full survey spectrum of the MWCNTs-ZrO<sub>2</sub> composite, which confirms the presence of C, O, and Zr elements. Figure 4b shows deconvoluated peaks for the Zr 3d spectrum at 183.7 and 186.2 eV, corresponding to Zr  $3d_{3/2}$  and Zr  $3d_{5/2}$ , respectively.<sup>[57a]</sup> Deconvoluated peaks at 284.9, 286.3, and 288.2 eV in the high-resolution C 1 s spectrum are associated with the C–C, C–O, and C=O functionalities, respectively.<sup>[57a]</sup> The fine spectrum of O 1 s in the as-prepared composite reveals peaks at 531.3, 532.4, and 533.5 eV, corresponding to Zr–O, C=O, and O–C=O, respectively.<sup>[57]</sup> All these findings point to the oxidized nature of MWCNTs and the presence of ZrO<sub>2</sub> in the MWCNTs-ZrO<sub>2</sub> composite.



**FIGURE 4** XPS spectra of MWCNTs-ZrO<sub>2</sub> composite: (a) full survey spectra, (b) Zr 3d, (c) C 1 s, and (d) O 1 s

## 2.2 | One-pot synthesis of pyrazole derivatives

The catalytic activity of MWCNTs-ZrO<sub>2</sub> was examined for the multicomponent reaction of substituted benzaldehydes, phenyl hydrazine, and malononitrile (Scheme 2). To optimize the suitable reaction conditions for the synthesis of pyrazole derivatives, *p*-nitro benzaldehyde (1 mmol), phenyl hydrazine (1 mmol), and malononitrile (1 mmol) were chosen as model reactants in the presence of MWCNTs-ZrO<sub>2</sub> nanocomposite and the results are summarized in Table 1. When the reaction was carried out in the absence of a catalyst, no product was formed after 10 hr at room temperature or at high temperature (Table 1, entries 1 and 2). The same reaction was performed in the presence of MWCNT (10 mg) and ZrO<sub>2</sub> (10 mg) in water (5 ml) as solvent at room temperature, giving the products in yields of 35% and 40%, respectively (Table 1, entries 3 and 4).

When the reaction was carried out in the presence of MWCNTs- $ZrO_2$  catalyst (10 mg), the yield of the product



**SCHEME 2** Synthesis of pyrazole derivatives **4** 

was 92% in water at room temperature (Table 1, entry 5). Solvents with different polarities, such as EtOH, MeOH, dichloromethane (DCM), MeCN, and H<sub>2</sub>O, were used to determine the best solvent and H<sub>2</sub>O was found to be the best reaction medium for the synthesis of pyrazole (Table 1, entries 1-11). It is noteworthy that there was no significant improvement in the yield of product on increasing the amount of catalyst from 10 mg to 20 mg (Table 1, entries 5 and 6). Further increasing the temperature had no effect on the yield of the desired product (Table 1, entry 11). After optimization of the reaction conditions, the scope of the reaction was extended by using different aromatic aldehydes, phenylhydrazine, and malononitrile to obtain the products 4a-p, which are summarized in Figure 5. In all cases, aromatic aldehydes containing electron-withdrawing as well as electrondonating compounds showed good to excellent yield. The structures of all products were characterized by FT-IR. <sup>1</sup>H NMR, and <sup>13</sup>C NMR spectroscopy analysis.

# 2.3 | One-pot synthesis of 1,2-disubstituted benzimidazole derivatives

As a result of the success of the synthesis of pyrazole reactions, the utility of the nanocomposite MWCNTs- $ZrO_2$  was extended to the synthesis of 1,2-disubstituted

**TABLE 1** Optimization of the reaction conditions for the synthesis of pyrazole **4a**<sup>[a]</sup>

	O <sub>2</sub> N CH	0 + + NC	CN MWCNTs-ZrO <sub>2</sub> Solvent, Temp. O <sub>2</sub> N	NH <sub>2</sub>	
Entry	Catalyst (mg)	Solvent	Temperature (°C)	Time (hr)	Yield (%) <sup>[b]</sup>
1	-	H <sub>2</sub> O	r.t.	10	-
2	-	H <sub>2</sub> O	60	10	-
3	MWCNT (10)	H <sub>2</sub> O	r.t.	5	35
4	$ZrO_{2}(10)$	H <sub>2</sub> O	r.t.	5	40
5	MWCNTs- $ZrO_2$ (10)	H <sub>2</sub> O	r.t.	1.5	92
6	MWCNTs- $ZrO_2(20)$	$H_2O$	r.t.	1.5	92
7	MWCNTs- $ZrO_2(10)$	EtOH	r.t.	1.5	88
8	MWCNTs- $ZrO_2(10)$	MeCN	r.t.	1.5	78
9	MWCNTs- $ZrO_2(10)$	DCM	r.t.	1.5	82
10	MWCNTs- $ZrO_2(10)$	MeOH	r.t.	1.5	85
11	MWCNTs-ZrO <sub>2</sub> (10)	H <sub>2</sub> O	60	1.5	92

<sup>a</sup>Reaction conditions: *p*-nitro benzaldehyde (1 mmol), phenylhydrazine (1 mmol), malononitrile (1 mmol), and MWCNTs-ZrO<sub>2</sub> nanocomposite in solvent (5 ml). <sup>b</sup>Isolated yield.



FIGURE 5 Synthesis of pyrazole derivatives in the presence of MWCNTs-ZrO<sub>2</sub> nanocomposite

benzimidazole by cyclocondensation of 1 mol of *o*-phenylenediamine and 2 mol of various benzaldehydes (Scheme 3).

At the outset of the present study and to optimize the reaction conditions for the synthesis of disubstituted benzimidazole derivatives, *o*-phenylenediamine (1 mmol) and *p*-hydroxybenzaldehyde (2 mmol) in the presence of MWCNTs-ZrO<sub>2</sub> nanocomposite with different solvents were chosen as a model reaction and the results are summarized in Table 2.

The cyclocondensations of *o*-phenylenediamine (1 mmol) and various aromatic benzaldehydes (2 mmol) with MWCNTs-ZrO<sub>2</sub> nanocomposite in EtOH under optimized reaction conditions are summarized in Figure 6. In all cases, aromatic aldehydes containing electron-withdrawing as well as electron-donating compounds showed good to excellent yield. The structures of the products **7a–o** were characterized by FT-IR, <sup>1</sup>H NMR, and <sup>13</sup>C NMR spectroscopy analysis.



**SCHEME 3** Synthesis of 1,2-disubstituted benzimidazole derivatives **7** 

## 2.4 | One-pot synthesis of 2-arylbenzazole derivatives

The outlook of *o*-substituted aniline system has been continued for the synthesis of 2-aryl benzimidazole and 2-aryl benzothiazole derivatives (Scheme 4) under the same reaction conditions as shown in Table 2 (entry 8).

For the synthesis of 2-aryl benzimidazole derivatives, *o*-phenylenediamine (1 mmol) and various aromatic benzaldehydes (1 mmol) with MWCNTs-ZrO<sub>2</sub> nanocomposite were stirred in EtOH. For the synthesis of 2-aryl benzothiazole derivatives, 2-aminothiophenol (1 mmol) was used instead of *o*-phenylenediamine with various aromatic aldehydes (1 mmol) and MWCNTs-ZrO<sub>2</sub> nanocomposite (10 mg) in EtOH. All compounds **9a–j** are summarized in Figure 7. From Figure 7, it is concluded that aromatic aldehydes containing electron-donating as well as electron-withdrawing compounds showed good to excellent yield. The structures of all products were characterized by FT-IR, <sup>1</sup>H NMR, and <sup>13</sup>C NMR spectros-copy analysis.

## 2.5 | One-pot synthesis of dihydroquinazolinone derivatives

The catalytic activity of MWCNTs-ZrO<sub>2</sub> was investigated for the synthesis of dihydroquinazolinone derivatives,

Applied Organometallic\_WILEY<sup>7 of 13</sup> Chemistry

#### TABLE 2 Optimization of the reaction conditions for the synthesis of disubstituted benzimidazole 7b<sup>[a]</sup>



Entry	Solvent/catalyst	Temperature (°C)	Time (hr)	Yield (%) <sup>[b]</sup>
1	H <sub>2</sub> O/10 mg	r.t.	2	40
2	$H_2O/20$ mg	r.t.	2	45
3	MeCN/10 mg	r.t.	2	50
4	DCM/10 mg	r.t.	2.5	60
5	CHCl <sub>3</sub> /10 mg	r.t.	2.5	62
6	MeOH/10 mg	r.t.	2	75
7	EtOH/10 mg	r.t.	2	85
8	EtOH/10 mg	r.t.	3	92
9	EtOH/20 mg	60	3	92

Bold emphasis highlight the optimal reaction conditions giving excellent yield.

<sup>a</sup>Reaction conditions: *o*-phenylenediamine (1 mmol), *p*-hydroxybenzaldehyde (2 mmol), and MWCNTs-ZrO<sub>2</sub> nanocomposite in solvent (5 ml).

<sup>b</sup>Isolated yield.



FIGURE 6 Synthesis of 1,2-disubstituted benzimidazole derivatives in the presence of MWCNTs-ZrO<sub>2</sub> nanocomposite

8 of 13 WILEY Organometallic Chemistry



**SCHEME 4** Synthesis of 2-arylbenzazole derivatives **9** 

keeping water as a solvent at room temperature (Scheme 5).

To optimize the reaction conditions, the reaction between 2-aminobenzamide (1 mmol) and 4-hydroxy-3,5-dimethoxy benzaldehyde (1 mmol) was used as a model reaction in the presence of MWCNTs- $ZrO_2$  nanocomposite and the results are summarized in Table 3.

The products obtained from the condensation of 2-aminobenzamide (1 mmol) and various aromatic benzaldehydes (1 mmol) with MWCNTs-ZrO<sub>2</sub> nanocomposite in H<sub>2</sub>O under optimal conditions are summarized in Figure 8 and have moderately good yield. The structures of compounds **12a–e** were characterized by FT-IR, <sup>1</sup>H NMR, and <sup>13</sup>C NMR spectroscopy analysis.

To demonstrate the efficiency of the present protocol, the results obtained for the synthesis of compounds **4f**, **7b**, **9h**, and **12b** were compared with some previous reported methods (Table 4). From Table 4, it is clear that the present system is comparable with reported procedures with respect to solvent and yields.

Catalyst reusability was screened for the synthesis of products **4f**, **7b**, **9h**, and **12b**. For compounds **4f** and **12b** the catalyst was recovered from the aqueous part of the reaction mixture after work-up with ethyl acetate. The catalyst was washed with EtOH and DCM several times, then dried in an oven at 60°C. For compounds **7b** and **9h**, the reaction mixtures were evaporated under reduced pressure to remove EtOH. The residues were extracted after a conventional work-up with ethyl



SCHEME 5 Synthesis of dihydroquinazolinone derivatives 12

acetate and water, and the catalyst was recovered by above stated procedure. In this way, the catalyst was recovered four times and a slight loss of catalytic activity was observed for each reaction. The results are shown in Figure 9.

#### 3 | EXPERIMENTAL

#### 3.1 | Materials and characterization

All reagents were purchased from Merck, Sigma-Aldrich, and Fluka, Bangalore. The reactions were monitored using precoated aluminum TLC plates (Mark silica 60, f<sub>254</sub>). XRD measurements were recorded at room temperature to characterize MWCNTs, oxidized MWCNTs, and MWCNTs-ZrO<sub>2</sub> using a Phillip, Holland, Bangalore instrument with CuK $\alpha$  radiation at  $\lambda = 0.1541$  nm. The morphology of the samples was studied by FE-SEM on a Carl Zeiss, Bangalore at an accelerating voltage of 20 kV. XPS of the nanocomposite was examined using a PHI 5000 Versa Probe II system, Bangalore using a microfocused (100 µm, 25 W, 15 kV) monochromatic Al K $\alpha$  source ( $h\nu = 1486.6$  eV). NMR spectra were recorded on a Bruker Avance, Bangalore 400 MHz, 500 MHz or 600 MHz spectrometer using DMSO-d<sub>6</sub> or CDCl<sub>3</sub> as the solvent. The multiplicity was marked as s (singlet), d (doublet), t (triplet), m (multiplet), and or (broad singlet). Melting points were determined in open capillary using an Electrothermal 9,100, Bangalore and were



**FIGURE 7** Synthesis of 2-arylbenzazole derivatives in the presence of MWCNTs-ZrO<sub>2</sub> nanocomposite

Applied Organometallic\_WILEY<sup>9</sup> of 13 Chemistry

#### TABLE 3 Optimization of the reaction conditions for the synthesis of dihydroquinazolinone 12e<sup>[a]</sup>



Bold emphasis highlight the optimal reaction conditions giving excellent yield.

<sup>a</sup>Reaction conditions: 2-aminobenzamide (1 mmol), 4-hydroxy-3,5-dimethoxy benzaldehyde (1 mmol), and MWCNTs-ZrO<sub>2</sub> nanocomposite in solvent (5 ml).

<sup>b</sup>Isolated yield.



**FIGURE 8** Synthesis of dihydroquinazolinone derivatives in the presence of MWCNTs-ZrO<sub>2</sub> nanocomposite

uncorrected. FT-IR spectra were recorded in the wavenumber range  $4,000-400 \text{ cm}^{-1}$  on a Perkin-Elmer, Bangalore FT-IR spectrometer RXI.

### 3.2 | Preparation of ZrO<sub>2</sub>

A solution (30 ml) of 0.3 M ZrO(NO<sub>3</sub>)<sub>2</sub>.H<sub>2</sub>O using coconut juice as solvent was vigorously stirred followed by ultrasonication for 30 min. Subsequently, the solution was subjected to refluxing at 100°C for 24 hr. Finally, the white product was washed with distilled water until neutral pH was obtained, then it was dried in a vacuum oven at 60°C.

## 3.3 | Preparation of MWCNTs-ZrO<sub>2</sub> composite

MWCNTs were chemically oxidized by refluxing using concentrated HNO<sub>3</sub> and to form products referred to as MWCNT Ox.<sup>[58]</sup> Next, 2 wt% of oxidized MWCNTs was added to 30 ml of 0.3 M ZrO(NO<sub>3</sub>)<sub>2</sub>.H<sub>2</sub>O solution using coconut juice as solvent with vigorous stirring followed by its ultrasonication for 30 min. Subsequently, the whole dispersion was refluxed at 100°C for 24 hr. The black product obtained was washed with distilled water until neutral pH was reached followed by drying in a vacuum oven at 60°C. This product is MWCNTs-ZrO<sub>2</sub>.

## 3.4 | General procedure for the synthesis of pyrazoles

A mixture of phenylhydrazine (1, 1 mmol), benzaldehyde (2, 1 mmol), manolonitrile (3, 1 mmol), and MWCNTs-ZrO<sub>2</sub> nanocomposite (10 mg) in 5 ml of water was stirred in a round-bottomed flask at room temperature for 1.5 hr. After completion of the reaction, the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and removed under reduced pressure. Finally, the residue was washed with water and recrystallized from ethanol to afford the pure products **4a–p**. The products were characterized by FT-IR, <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic analysis.

Sl no.	Compound	Catalyst	Condition	Yield (%)	Reference				
1	4f	I <sub>2</sub>	Water/r.t./6 min	92	[11]				
2		PEG:H <sub>2</sub> O	Ultrasonic irradiation/45 min	90	[13]				
3		CuO/ZrO <sub>2</sub>	Water/40°C/1.5 hr	89	[14]				
4		Fe <sub>3</sub> O <sub>4</sub> @Si@MoO <sub>2</sub>	Solvent-free/r.t./20 min	90	[16]				
5		MWCNTs-ZrO <sub>2</sub>	Water/r.t./1.5 hr	92	This work				
6		Ionic liquid-coated ZnO nanoparticles	Ball mill/r.t./22 min	95	[25]				
7		Chitosan-supported Fe <sub>3</sub> O <sub>4</sub>	EtOH/r.t./4.5 hr	91	[26]				
8	7b	TFE	r.t./30 min	93	[28]				
9		SDS micelles	Water/25°C/10 min	94	[29]				
10		MWCNTs-ZrO <sub>2</sub>	Water/r.t./3 hr	92	This work				
11	9h	SDS micelles	Water/25°C/10 min	95	[29]				
12		Bu <sup>t</sup> ONa	Toluene/100°C/24 hr	76	[33]				
13		MWCNTs-ZrO <sub>2</sub>	Water/r.t./1.5 hr	90	This work				
14	12b	PEG-400	100–110°C	84	[35]				
15		β-CD	Water/55–60°C	84	[37]				
16		$[Ce(L-Pro)_2]_2$ (Oxa)	EtOH/50-55°C	81	[40]				
17		MWCNTs-ZrO <sub>2</sub>	Water/r.t./3 hr	85	This work				

**TABLE 4** Comparison of synthesis of products **4f** (entries 1–5), **7b** (entries 6–10), **9h** (entries 11–13), and **12b** (entries 14–17) with reported protocols

ButONa, Sodium tert-butoxide; CuO, Copper (II) oxide; EtOH, ethanol;  $Fe_3O_4$ , Iron oxide;  $H_2O =$  Water;  $I_2$ , Iodine; L-Pro, L-Proline; MoO<sub>2</sub>, Molybdenum dioxide; MWCNTs-ZrO2, multi-walled carbonnanotubes-zirconia; Oxa, Oxalate; PEG, Polyethylene glycol; PEG-400, Polyethylene glycol-400; SDS, Sodium dodecyl sulfate; TFE, Trifluoroethanol; ZnO, Zirconia;  $\beta$ -CD, beta-cyclodextrin.





## 3.5 | General procedure for the synthesis of 1,2-disubstituted benzimidazoles

A mixture of *o*-phenylenediamine (5, 1 mmol), benzaldehyde (6, 2 mmol), and MWCNTs- $ZrO_2$  (10 mg) in 5 ml of ethanol was stirred in a round-bottomed flask at room temperature for 3 hr. After completion of the reaction, the solvent was removed under reduced pressure and the residue was extracted with ethyl acetate and water. The ethyl acetate extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and removed under reduced pressure. Finally, the residue was washed with water and methanol to afford the pure products **7a–o**. The products were characterized by FT-IR, <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic analysis.

### 3.6 | General procedure for the synthesis of 2-aryl benzimidazoles and 2-aryl benzothiazoles

A mixture of *o*-phenylenediamine (**5a**, 1 mmol), benzaldehyde (**8**, 1 mmol), and MWCNTs- $ZrO_2$  (10 mg) in 5 ml of ethanol was stirred in a round-bottomed flask at room temperature for 2 hr. After completion of the reaction, an identical procedure (serial no. **3.5**) was adopted to get pure products **9a–e**. A similar procedure was used for reaction of *o*-aminothiophenol (**5b**, 1 mmol) and benzaldehyde (**8**, 1 mmol) in the presence of MWCNTs-ZrO<sub>2</sub> (10 mg) for the synthesis of 2-aryl benzothiazoles **9f–j**. The products were characterized by FT-IR, <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic analysis.

## 3.7 | General procedure for the synthesis of dihydroquinazolinones

A mixture of anthranilamide (**10**, 1 mmol), benzaldehyde (**11**, 1 mmol), and MWCNTs-ZrO<sub>2</sub> (10 mg) in 5 ml of water was stirred in a round-bottomed flask at room temperature for 4 hr. After completion of the reaction, the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. Finally, the residue was washed with water and recrystallized from ethanol to afford the pure products **12a–e**. The products were characterized by FT-IR, <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic analysis.

### 3.8 | Spectral data for selected compounds

### 3.8.1 | 5-amino-3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (4b)

White solid, m.p.  $130-132^{\circ}$ C.<sup>[11]</sup> IR (KBr)  $v_{max}$ : 3312, 3,035, 2,234, 1,679, 1,585, 1,490, 1,257, 1,089, 746 cm<sup>-1</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.64 (s, 2H), 7.60 (d, 2H, J = 8.3 Hz), 7.36 (d, 2H, J = 8.3 Hz), 7.32–7.28 (m, 2H), 7.13 (d, 2H, J = 7.9 Hz), 6.92 (t, 1H, J = 7.2 Hz) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$ : 158.3, 144.4, 135.9, 134.0, 133.9, 131.8, 130.1, 129.4, 128.8, 127.3, 120.4, 112.8 ppm.

### 3.8.2 | 5-amino-3-(4-hydroxy-3,5-dimethoxyphenyl)-1-phenyl-1*H*pyrazole-4-carbonitrile (40)

Orange oil. IR (KBr)  $v_{\text{max}}$ : 3453, 2,932, 2,214, 1,592, 1,497, 1,453, 1,112 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 10.10 (s, 1H), 8.55 (s, 1H), 7.73 (s, 1H), 7.18 (t, 2H, J = 7.4 Hz), 7.03 (d, 2H, J = 7.9 Hz), 6.89 (s, 2H), 6.69 (t, 1H, J = 7.2 Hz), 3.79 (s, 6H) ppm. <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 148.6, 146.0, 137.7, 136.6, 129.5, 126.7, 118.7, 112.3, 103.7, 56.4 ppm.

## 3.8.3 | 1-(4-methylbenzyl)-2-(*p*-tolyl)-1*H*benzimidazole (7a)

White solid, m.p.  $128-130^{\circ}$ C.<sup>[28]</sup> IR (KBr)  $v_{max}$ : 2941, 1,609, 1,516, 1,451, 748 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.89 (d, 1H, J = 8.0 Hz), 7.61 (d, 2H, J = 7.9 Hz), 7.32–7.28 (m, 1H), 7.25 (d, 2H, J = 7.7 Hz), 7.20 (d, 2H, J = 5.7 Hz), 7.13 (d, 2H, J = 7.7 Hz), 6.99 (d, 2H, J = 7.7 Hz), 5.39 (s, 2H), 2.40 (s, 3H), 2.33 (s, 3H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 154.3, 143.2, 140.1, 137.4, 136.1, 133.5, 129.7, 129.5, 129.2, 127.2, 125.9, 122.9, 122.6, 119.8, 110.6, 48.2, 21.5, 21.1 ppm.

### 3.8.4 | 1-(4-hydroxy-3-chloro-benzyl)-2-(4-hydroxy-3-chloro-phenyl)-1Hbenzimidazole (7j)

White solid, m.p. 232°C. IR (KBr)  $v_{max}$ : 3407, 2,532, 1,600, 1,407, 745 cm<sup>-1</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 10.82 (s, 1H), 10.23 (s, 1H), 7.69 (s, 2H), 7.51 (dd, 2H, J = 12.8, 5.9 Hz), 7.25–7.24 (m, 2H), 7.11 (d, 1H, J = 8.4 Hz), 7.03 (s, 1H), 6.87 (d, 1H, J = 8.4 Hz), 6.74 (d, 1H, J = 8.4 Hz), 5.45 (s, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 155.0, 152.9, 152.6, 143.0, 136.3, 131.0, 129.4, 129.1, 128.3, 126.4, 123.1, 122.7, 122.3, 120.5, 120.3, 119.6, 117.4, 117.2, 111.5, 47.0 ppm.

### 3.8.5 | 2-(4-hydroxy-3-ethoxyphenyl)-1*H*benzimidazole (9d)

Chrome yellow solid, m.p. 108–110°C.<sup>[59]</sup> IR (KBr)  $v_{\text{max}}$ : 3273, 2,914, 2,391, 1,587, 1,451, 1,265 cm<sup>-1</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 12.65 (bs, 1H), 9.48 (s, 1H), 7.74 (s, 1H), 7.62 (dd, 1H, J = 8.1, 1.1 Hz), 7.55 (s, 2H), 7.16 (dd, 2H, J = 5.5, 2.9 Hz), 6.94 (d, 1H, J = 8.2 Hz), 4.15 (q, 2H, J = 6.9 Hz), 1.40 (t, 3H, J = 6.9 Hz) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 152.3, 149.2, 147.4, 122.1, 121.9, 120.1, 116.2, 112.0, 64.4, 15.2 ppm.

### 3.8.6 | 2-(4-nitrophenyl)-benzothiazole (9g)

Yellow solid, m.p. 230–232°C.<sup>[29]</sup> IR (KBr)  $v_{max}$ : 3051, 1,630, 1,602, 1,502, 1,336, 763 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 8.09 (d, 1H, J = 8.1 Hz), 8.06 (d, 2H, J = 8.4 Hz), 7.93 (d, 1H, J = 7.9 Hz), 7.54–7.49 (m, 3H), 7.43 (t, 1H, J = 7.6 Hz) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 166.6, 154.1, 137.1, 135.1, 132.2, 129.3, 128.7, 126.5, 125.4, 123.3, 121.7 ppm.

### 3.8.7 | 2-(3,4-dihydroxyphenyl)-2,3-dihydroquinazolin-4(1*H*)-one (12b)

White solid, m.p. 291–293°C.<sup>[35]</sup> IR (KBr)  $v_{\text{max}}$ : 3402, 3,244, 3,158, 1,645, 1,616, 1,508, 1,265 cm<sup>-1</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 9.02 (s, 1H), 8.98 (s, 1H), 8.07 (s, 1H), 7.61 (d, 1H, J = 6.6 Hz), 7.23 (d, 1H, J = 6.6 Hz), 6.92 (s, 2H), 6.724 (s,), 6.66 (d, 3H, J = 6 Hz), 5.58 (s, 1H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-d<sub>6</sub>)  $\delta$ : 164.2, 148.5, 146.1, 145.5, 133.7, 132.8, 127.8, 118.5, 117.4, 115.5, 115.3, 114.8, 114.7, 67.1 ppm.

#### 4 | CONCLUSION

MWCNTs-ZrO<sub>2</sub> nanocomposite was successfully synthesized from the natural feedstock ACC, which acts as a green, environmentally friendly, and nontoxic solvent. Because of the acidic nature of ACC, it is the main source of protons and stimulates the formation of MWCNTs-ZrO<sub>2</sub>. The nanocomposite was characterized by FT-IR, XRD, FE-SEM, and XPS analysis. It is noteworthy that the synthesized nanocomposite was used as a heterogeneous and reusable nanocatalyst in the field of organic synthesis for the first time. Various N-heterocyclic compounds such as pyrazoles, disubstituted benzimidazoles, 2-arylbenzazoles, and dihydroquinazolinones were synthesized using the MWCNTs-ZrO<sub>2</sub> nanocomposite under ecofriendly reaction conditions. The major advantages of the protocol are short reaction time, good to excellent yield, green reaction conditions, and recyclability without significant loss in catalytic activity, and these factors open up a new horizon in organic synthesis.

#### ACKNOWLEDGMENTS

We thank University Grants Commission, New Delhi for financial support of this work [Ref No.- 21/06/2015(i)EU-V].

#### ORCID

Bipasa Halder b https://orcid.org/0000-0002-0138-9084 Flora Banerjee b https://orcid.org/0000-0003-3257-8942 Ahindra Nag https://orcid.org/0000-0001-5924-8981

#### REFERENCES

- a) Z.-Y. Mao, X.-Y. Liao, H.-S. Wang, C.-G. Wang, K.-B. Huang, Y.-M. Pan, *RSC Adv.* 2017, 7, 13123. b) A. Kumar, D. Saxena, M. K. Gupta, *Green Chem.* 2013, *15*, 2699.
   c) A. P. Rajput, A. R. Kankhare, *Int. J. Pharm. Sci. Invent.* 2017, 6, 19.
- [2] R. Sridhar, P. T. Perumal, S. Etti, G. Shanmugam, M. N. Ponnuswamy, V. R. Prabavathy, N. Mathivanan, *Bioorg. Med. Chem. Lett.* 2004, 14, 6035.

- [3] A. A. Bekhit, H. T. Y. Fahmy, S. A. F. Rostom, A. M. Baraka, *Eur. J. Med. Chem.* 2003, 38, 27.
- [4] O. I. El-Sabbagh, M. M. Baraka, S. M. Ibrahim, C. Pannecouque, G. Andrei, R. Snoeck, J. Balzarini, A. A. Rashad, *Eur. J. Med. Chem.* 2009, 44, 3746.
- [5] G. R. Bebernitz, G. Argentieri, B. Battle, C. Brennan, B. Balkan, B. F. Burkey, M. Eckhardt, J. Gao, P. Kapa, R. J. Strohschein, H. F. Schuster, M. Wilson, D. D. Xu, *J. Med. Chem.* **2001**, *44*, 2601.
- [6] S. Manfredini, R. Bazzanini, P. G. Baraldi, M. Bonora, M. Marangoni, D. Simoni, A. Pani, F. Scintu, E. Pinna, L. Pisano, P. La Colla, *Anti-Cancer Drug des.* **1996**, *11*, 193.
- [7] S. G. Alegaon, K. R. Alagawadi, M. K. Garg, K. Dushyant, D. Vinod, *Bioorg. Chem.* 2014, 54, 51.
- [8] G. Menozzi, L. Mosti, P. Fossa, F. Mattioli, M. Ghia, J. Heterocycl. Chem. 1997, 34, 963.
- [9] D. M. Bailey, P. E. Hansen, A. G. Hlavac, E. R. Baizman, J. Pearl, A. F. DeFelice, M. E. Feigenson, J. Med. Chem. 1985, 28, 256.
- [10] Z. Özdemir, H. B. Kandilci, B. Gümüşel, U. Çalış, A. A. Bilgin, *Eur. J. Med. Chem.* **2007**, *42*, 373.
- [11] xM. Srivastava, P. Rai, J. Singh, J. Singh, New J. Chem. 2014, 38, 302.
- [12] S. Kumari, A. Shekhar, D. D. Pathak, New J. Chem. 2016, 40, 5053.
- [13] F. Nemati, S. H. Nikkhah, A. Elhampour, *Chin. Chem. Lett.* 2015, 26, 1397.
- [14] S. Maddila, S. Rana, R. Pagadala, S. Kankala, S. Maddila, S. B. Jonnalagadda, *Catal. Commun.* 2015, 61, 26.
- [15] M. A. Zolfigol, F. Afsharnadery, S. Baghery, S. Salehzadeh, F. Maleki, RSC Adv. 2015, 5, 75555.
- [16] J. Rakhtshah, S. Salehzadeh, E. Gowdini, F. Maleki, S. Baghery, M. A. Zolfigol, *RSC Adv.* 2016, *6*, 104875.
- [17] P. Arora, J. K. Rajput, J. Mater. Sci. 2017, 52, 11413.
- [18] E. S. Lazer, M. R. Matteo, G. J. Possanza, J. Med. Chem. 1987, 30, 726.
- [19] G. Navarette-Vázquez, R. Cedillo, A. Hernández-Campos, A. Yépez, F. Hernández-Luis, J. Valdez, R. Morales, R. Cortés, M. Hernández, R. Castillo, *Bioorg. Med. Chem. Lett.* 2001, 11, 187.
- [20] A. T. Mavrova, P. Denkova, Y. A. Tsenov, K. K. Anichina, D. I. Vutchev, *Bioorg. Med. Chem.* **2007**, *15*, 6291.
- [21] N. S. Pawar, D. S. Dalal, S. R. Shimpi, P. P. Mahulikar, Eur. J. Pharm. Sci. 2004, 21, 115.
- [22] K. Starčević, M. Kralj, K. Ester, I. Sabol, M. Grce, K. Pavelić, G. Karminski-Zamola, *Bioorg. Med. Chem.* 2007, 15, 4419.
- [23] H. Zarrinmayerh, D. M. Zimmerman, B. E. Cantrell, D. A. Schober, R. F. Bruns, S. L. Gackenheimer, P. L. Orustein, P. A. Hipskind, T. C. Britton, D. R. Gehlert, *Bioorg. Med. Chem. Lett.* **1999**, *9*, 647.
- [24] R. K. Jat, J. L. Jat, D. P. Pathak, E-J. Chem. 2006, 3, 278.
- [25] H. Sharma, N. Kaur, N. Singh, D. O. Jang, Green Chem. 2015, 17, 4263.
- [26] A. Maleki, N. Ghamari, M. Kamalzare, RSC Adv. 2014, 4, 9416.
- [27] V. Ravi, E. Ramu, K. Vijay, A. S. Rao, Chem. Pharm. Bull. 2007, 55, 1254.
- [28] R. Chebolu, D. N. Kommi, D. Kumar, N. Bollineni, A. K. Chakraborti, J. Org. Chem. 2012, 77, 10158.
- [29] K. Bahrami, M. M. Khodaei, A. Nejati, Green Chem. 2010, 12, 1237.

- [30] N. H. Cano, J. G. Uranga, M. Nardi, A. Procopio, D. A. Wunderlin, A. N. Santiago, *Beilstein J. Org. Chem.* 2016, 12, 2410.
- [31] M. Karthik, P. Suresh, New J. Chem. 2018, 42, 17931.
- [32] D. Kommula, S. R. M. Madugula, J. Iran. Chem. Soc. 2017, 14, 1665.
- [33] X. Shi, J. Guo, J. Liu, M. Ye, Q. Xu, Chem. Eur. J. 2015, 21, 9988.
- [34] S. Sharma, D. Bhattacherjee, P. Das, Org. Biomol. Chem. 2018, 16, 1337.
- [35] P. Yerram, R. Chowrasia, S. Seeka, S. J. Tangenda, Eur. J. Chem. 2013, 4, 462.
- [36] M. Dabiri, P. Salehi, M. Baghbanzadeh, M. A. Zolfigol, M. Agheb, S. Heydari, *Catal. Commun.* 2008, 9, 785.
- [37] K. Ramesh, K. Karnakar, G. Satish, B. S. P. A. Kumar, Y. V. D. Nageswar, *Tetrahedron Lett.* 2012, 53, 6936.
- [38] J. Safari, S. Gandomi-Ravandi, C. R. Chim. 2013, 16, 1158.
- [39] P. Salehi, M. Dabiri, M. Baghbanzadeh, M. Bahramnejad, Synth. Commun. 2006, 36, 2287.
- [40] R. Katla, R. Chowrasia, C. D. G. da Silva, A. R. de Oliveira, B. F. dos Santos, N. L. C. Domingues, *Synthesis* 2017, 49, 5143.
- [41] a) A. Baiker, Chem. Rev. 1999, 99, 453. b) S.-H. Lee,
  S. T. Kadam, Appl. Organomet. Chem. 2011, 25, 608.
  c) A. Corma, H. García, F. X. L. Xamena, Chem. Rev. 2010, 110, 4606. d) Z. Guo, B. Liu, Q. Zhang, W. Deng, Y. Wang, Y. Yang, Chem. Soc. Rev. 2014, 43, 3480. e) M. Rohaniyan, A. Davoodnia, A. Nakhaei, Appl. Organomet. Chem. 2016, 30, 626.
- [42] a) G. I. Shakibaei, P. Mirzaei, A. Bazgir, *Appl. Catal. A: Gen.* **2007**, 325, 188. b) H. Veisi, M. R. P. Heravi, M. Hamelian, *Appl. Organomet. Chem.* **2015**, 29, 334.
- [43] M. Melchionna, S. Marchesan, M. Prato, P. Fornasiero, Catal. Sci. Technol. 2015, 5, 3859.
- [44] G. G. Wildgoose, C. E. Banks, R. G. Compton, Small 2006, 2, 182.
- [45] a) J. Safari, S. Gandomi-Ravandi, J. Mol. Catal. A: Chem. 2014, 390, 1. b) H. He, L. A. Pham-Huy, P. Dramou, D. Xiao, P. Zuo, C. Pham-Huy, BioMed Res. Int. 2013, 2013, 578290.
- [46] a) K. Tanabe, *Mater. Chem. Phys.* 1985, *13*, 347. b) G. D. Wilk,
  R. M. Wallace, J. M. Anthony, *J. Appl. Phys.* 2001, *89*, 5243.
  c) R. C. Garvie, R. H. Hannink, R. T. Pascoe, *Nature* 1975, 258, 703.
- [47] a) A. H. Heuer, L. W. Hobbs, Sci. Technol. Zirconia am. Ceramic Soc. Columbus Ohio 1981, 3, 241. b) A. Krell, J. Klimke, T. Hutzler, Opt. Mater. 2009, 31, 1144. c) J. Robertson, Rep. Prog. Phys. 2006, 69, 327. d) G. Liu, Y. Lin, Anal. Chem. 2005, 77, 5894. e) M. Inoue, H. Kominami, T. Inui, Appl. Catal. A: Gen. 1993, 97, L25. f) J. Joo, T. Yu, Y. W. Kim, H. M. Park, F. Wu, J. Z. Zhang, T. Hyeon, J. Am. Chem. Soc. 2003, 125, 6553. g) R. C. Buchanan, S. Pope, J. Electrochem. Soc. 1983, 130, 962. h) X. Luo, A. Morrin, A. J. Killard, M. R. Smyth, Electroanalysis 2006, 18, 319. i) S. A. Steiner, T. F. Baumann, B. C. Bayer, R. Blume, M. A. Worsley, W. J. MoberlyChan, E. L. Shaw, R. Schlögl, A. J. Hart, S. Hofmann, B. L. Wardle, J. Am. Chem. Soc. 2009, 131, 12144. j) J. Lu, J. B. Zang, S. X. Shan, H. Huang, Y. H. Wang, Nano Lett. 2008, 8, 4070. k) T. Z. Sholklapper, V. Radmilovic, C. P. Jacobson, S. J. Visco, L. C. De Jonghe, Electrochem. Solid-State Lett. 2007, 10, B74.
- [48] K. Ghosh, S. K. Srivastava, S. Puravankara, J. Nanosci. Nanotechnol. 2019, 19, 3367.

- [49] a) E. Kolvari, M. A. Zolfigol, H. Banary, *Chin. Chem. Lett.* **2011**, *22*, 1305. b) B. Maleki, N. Nasiri, R. Tayebee, A. Khojastehnezhad, H. A. Akhlaghi, *RSC Adv.* **2016**, *6*, 79128..
- [50] Selected references:a) R. Pal, Int. J. Adv. Chem. 2014, 2, 27.
  b) S. D. Bagul, J. D. Rajput, R. S. Bendre, Environ. Chem. Lett. 2017, 15, 725. c) H. V. Chavan, B. P. Bandgar, ACS Sustainable Chem. Eng. 2013, 1, 929. d) G. Kumaraswamy, S. Ramesh, Green Chem. 2003, 5, 306. e) A. N. Geraldes, A. A. da Silva, J. Leal, G. M. Estrada-Villegas, N. Lincopan, K. V. Katti, A. B. Lugão, Adv. Nanoparticles 2016, 5, 176. f) E. K. Elumalai, K. Kayalvizhi, S. Silvan, J. Pharm. Bioall. Sci. 2014, 6, 241.
  g) S. Naghdi, M. Sajjadi, M. Nasrollahzadeh, K. Y. Rhee, S. M. Sajadi, B. Jaleh, J. Taiwan Inst. Chem. E. 2018, 86, 158.
- [51] a) A. Prades, M. Dornier, N. Diop, J.-P. Pain, *Fruits* 2012, 67, 157. b) J. W. H. Yong, L. Ge, Y. F. Ng, S. N. Tan, *Molecules* 2009, 14, 5144. c) K. Misra, H. S. Maity, S. Chanda, A. Nag, *J. Mol. Catal. B: Enzym.* 2012, 82, 92.
- [52] A. Nikam, T. Pagar, S. Ghotekar, K. Pagar, S. Pansambal, J. Chem. Rev. 2019, 1, 154.
- [53] a) L. Stobinski, B. Lesiak, L. Kövér, J. Tóth, S. Biniak, G. Trykowski, J. Judek, J. Alloys Compd. 2010, 501, 77.
  b) H. Fayazfar, A. Afshar, A. Dolati, Mater. Sci. Appl. 2013, 4, 667. c) H. M. Altass, A. E. R. S. Khder, J. Mol. Catal. A: Chem. 2016, 411, 138. d) E. F. Lopez, V. S. Escribano, M. Panizza, M. M. Carnasciali, G. Busca, J. Mater. Chem. 2001, 11, 1891.
- [54] S. Giri, D. Ghosh, C. K. Das, Adv. Funct. Mater. 2014, 24, 1312.
- [55] a) S. Sankal, C. Kaynak, J. Reinf. Plast. Compos. 2013, 32, 75.
  b) A. S. K. Kumar, S.-J. Jiang, W.-L. Tseng, J. Mater. Chem. A 2015, 3, 7044.
- [56] a) P. Su, X. Ji, C. Liu, W. Gao, R. Fu, C. Tang, B. Cheng, *RSC Adv.* 2015, 5, 36467. b) G. Wang, L. Chen, Y. Sun, J. Wu, M. Fu, D. Ye, *RSC Adv.* 2015, 5, 45320.
- [57] a) P. K. Gupta, S. Tiwari, Z. H. Khan, P. R. Solanki, J. Mater. Chem. B 2017, 5, 2019. b) J. Zhou, X. Zha, F. Y. Chen, Q. Ye, P. Eklund, S. Du, Q. Huang, Angew. Chem. Int. Ed. 2016, 55, 5008.
- [58] I. D. Rosca, F. Watari, M. Uo, T. Akasaka, *Carbon* **2005**, *43*, 3124.
- [59] E. A. Dikusar, V. I. Potkin, Russ. J. Org. Chem. 2010, 46, 268.
- Note. r.t., room temperature.

Note. r.t., room temperature.

Note. r.t., room temperature.

#### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Halder B, Banerjee F, Nag A. MWCNTs-ZrO<sub>2</sub> as a reusable heterogeneous catalyst for the synthesis of *N*-heterocyclic scaffolds under green reaction medium. *Appl Organomet Chem*. 2020;e5906. https://doi.org/10.1002/aoc.5906

#### Applied Organometallic\_WILEY<sup>13 of 13</sup> Chemistry